[Inappropriate commercial presentation of selected drugs and associated overcost].
Toledano Mayoral
G
G
Salmerón García
A
A
Román Márquez
E
E
Cabeza Barrera
J
J
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics*; D001897:Boronic Acids / Q000008:administration & dosage / Q000191:economics*; D000069286:Bortezomib; D003365:Costs and Cost Analysis; D004304:Dosage Forms / Q000592:standards*; D004345:Drug Industry / Q000592:standards*; D004872:Ergocalciferols / Q000008:administration & dosage / Q000191:economics*; D000069285:Infliximab; D011166:Porphyrins / Q000008:administration & dosage / Q000191:economics*; D011719:Pyrazines / Q000008:administration & dosage / Q000191:economics*; D000077362:Verteporfin
D000911:Antibodies, Monoclonal; D001897:Boronic Acids; D004304:Dosage Forms; D004872:Ergocalciferols; D011166:Porphyrins; D011719:Pyrazines; D000077362:Verteporfin; C084656:paricalcitol; D000069286:Bortezomib; D000069285:Infliximab